Cisplatine : interactions médicamenteuses

Cisplatine (Platinol) présente 21 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 6 de niveau majeur, 7 de niveau modéré, 8 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (6)

  • Fatal bleomycin pulmonary toxicity has been reported in a patient with unrecognized cisplatin-induced oliguric renal failure. (notice Bléomycine, Interactions médicamenteuses)

  • GentamicineaminosideMajeure

    Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as cisplatin, cephaloridine, kanamycin, amikacin, neomycin, polymyxin B, colistin, paromomycin, streptomycin, tobramycin, vancomycin, and viomycin, should be avoided (see PRECAUTIONS, Drug Interactions section). (notice Gentamicine, Mise en garde encadrée)

  • NéomycineaminosideMajeure

    Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. (notice Néomycine, Mise en garde encadrée)

  • Pentamidinemédicament allongeant l'intervalle QTMajeure

    Because the nephrotoxic effects may be additive, the concomitant or sequential use of Pentamidine Isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible. (notice Pentamidine, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    …magnesium hydroxide Prevention or Management: Phenytoin and antacids should not be taken at the same time of day Antineoplastic agents (usually in combination) Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (notice Phénytoïne, Interactions médicamenteuses)

  • SorafénibMajeure

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (notice Sorafénib, Mises en garde et précautions)

Interactions modérées (7)

  • FosphénytoïneanticonvulsivantModérée

    …phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels Antineoplastic agents usually in combination Bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate Antiviral agents Fosamprenavir, nelfinavir, ritonavir Antiepileptic drugs Carbamazepine, vigabatrin Other Chronic alcohol abuse, diazepam, diazoxide,… (notice Fosphénytoïne, Interactions médicamenteuses)

  • Furosémidediurétique de l'anseModérée

    • Cisplatin and nephrotoxic drugs : Risk of ototoxicity and nephrotoxicity ( 7.1 ) (notice Furosémide, Interactions médicamenteuses)

  • IfosfamideModérée

    Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. (notice Ifosfamide, Mises en garde et précautions)

  • RituximabimmunosuppresseurModérée

    Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. (notice Rituximab, Mises en garde et précautions)

  • TacrolimusimmunosuppresseurModérée

    The risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors). (notice Tacrolimus, Mises en garde et précautions)

  • TrilaciclibModérée

    Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin) [see Clinical Pharmacology ( 12.3 )]. (notice Trilaciclib, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueModérée

    The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. (notice Vérapamil, Interactions médicamenteuses)

Mentions mineures (8)

  • Closely evaluate the renal function of patients Examples: Aminoglycosides, amphotericin B, systemic bacitracin, cisplatin, cyclosporine, foscarnet, or parenteral vancomycin Angiotensin Converting Enzyme (ACE) Inhibitors Clinical Impact: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due… (notice Butalbital, aspirine, caféine et codéine, Interactions médicamenteuses)

  • DocétaxelMineure

    In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (notice Docétaxel, Mises en garde et précautions)

  • MelphalanMineure

    Cisplatin may affect melphalan kinetics by inducing renal dysfunction and subsequently altering melphalan clearance. (notice Melphalan, Interactions médicamenteuses)

  • Ondansétronmédicament allongeant l'intervalle QTMineure

    Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. (notice Ondansétron, Interactions médicamenteuses)

  • PémétrexedantimétaboliteMineure

    …(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (notice Pémétrexed, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneMineure

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (notice Spironolactone, Mises en garde et précautions)

  • Torasémidediurétique de l'anseMineure

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (notice Torasémide, Mises en garde et précautions)

  • Myelosuppression Myelosuppression, manifested by neutropenia, anemia and thrombocytopenia, occur in patients receiving vinorelbine as a single agent and in combination with cisplatin [see Adverse Reactions ( 6.1 , 6.2 )] . (notice Vinorelbine, Mises en garde et précautions)

Vérifiez Cisplatine avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.